INB-100 After HSCT Shows Enduring Efficacy in Complex Leukemias
Early INB-100 results showed the potential to achieve durable remissions and improve survival in patients with complex leukemias, particularly AML.
A Look at Upcoming Impactful Presentations at ASCO GU 2025
The 2025 Genitourinary Cancers Symposium will feature key updates in the management of different bladder, prostate, and kidney cancer populations.
Retreatment With Pertuzumab/T-DM1 Improves PFS in HER2+ Breast Cancer
Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.
T-DXd Approval Appears Significant in HER2-Low/Ultralow Breast Cancer
Aditya Bardia, MD, MPH, FASCO, spoke about how the FDA approval of T-DXd in HER2-low or ultralow breast cancer will allow for a broader treatment range.
Creating a Collaborative Edge Through the MZL Workshop
Julie M. Vose, MD, MBA, answered questions about the significance and potential impact of MZL Workshop.
FDA OKs Brentuximab Vedotin Combo in R/R Large B-Cell Lymphoma
Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.
Objective Data Highlight Substantial Benefits With Mirdametinib in NF1-PN
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Data Open The Door for Earlier Sotorasib/Panitumumab Use in KRAS G12C+ CRC
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Mirdametinib Approval Brings Tumor Shrinkage and QOL Advantages to NF1-PN
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
FDA Approves Mirdametinib in Adult/Pediatric NF1-PN
Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.
FDA Accepts Linvoseltamab BLA for Review in R/R Multiple Myeloma
Efficacy results from the phase 1/2 LINKER-MM1 trial evaluating linvoseltamab in relapsed or refractory multiple myeloma support the decision.
Nodal Marginal Zone Lymphoma and Its Diagnostic Challenges
A pathologist discusses the challenges of diagnosing nodal MZL, including its lack of specific defining characteristics.
FDA Grants Fast Track Designation to Amezalpat Combination in HCC
Amezalpat plus atezolizumab and bevacizumab achieved a 6-month increase for OS compared with atezolizumab and bevacizumab alone in patients with HCC.
Improvements Over Chemo Yield Sotorasib Combo Approval in KRAS G12C+ CRC
Adding panitumumab to sotorasib has yielded higher responses rates in KRAS G12C-mutated CRC compared with prior standards of care.
Breast Cryoablation Inhibits Recurrence, Enhances Survival in Breast Cancer
Findings from the ICE3 trial revealed that no serious adverse effects were experienced related to the use of cryoablation in ipsilateral breast tumors.
Sotorasib Combo Approval is ‘Welcome Step’ in KRAS G12C+ CRC Care
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
ASH Top Takeaways of Bispecific Antibodies in R/R Multiple Myeloma
Hematologists gathered to discuss recent updates on bispecific antibodies surrounding patients with relapsed/refractory multiple myeloma.
Liso-cel Demonstrates Significant Responses in Relapsed/Refractory MZL
In the phase 2 TRANSCEND FL trial, lisocabtagene maraleucel met its primary end point of overall response rate in patients with marginal zone lymphoma.
Insights, Knowledge Gaps, and Priorities in Marginal Zone Lymphoma Research
Marginal Zone Lymphoma experts discussed recent advancements in all areas of MZL, while calling attention to gaps in knowledge in the 2024 MZL Scientific Workshop.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival
A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.
Clinical Trials Underestimate HRQOL Burden on R/R Myeloma Population
A retrospective systemic literature review showed that increased lines of therapy led to decreased HRQOL in patients with relapsed/refractory myeloma.
Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer
The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases.
Orphan Drug Designation Granted to 225Ac-SSO110 for SCLC
Following promising results from a trial investigating the effects of 225Ac-SSO110 on Balb/c nude mice injected with the xenograft model of SCLC, IND clearance was granted by the FDA.
Hormone Therapy Confers Modest Breast Cancer Risk Even With Family History
Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.
Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective
Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.
FT596 Shows Favorable Tolerability, Response Rate in B-Cell Lymphoma
Completion of the phase 1 first-in-human trial revealed that iPSC-derived CAR natural killer cell therapy has potential for development across oncology.
Program Evaluating TIDAL-01 in Solid Tumors Has Been Discontinued
The decision impacts the phase 1 STARLING trial and additional phase 1 trials sponsored by the Moffitt Cancer Center evaluating TIDAL-01 in solid tumors.
Ziftomenib Monotherapy Shows Positive Topline Results in NPM1-Mutant AML
Ziftomenib elicited positive responses in patients with NPM1-mutant acute myeloid leukemia, meeting the primary end point of the phase 2 KOMET-001 trial.
MZL Workshop Paves the Way for Better Treatment Options
Thomas Habermann, MD, discusses the significance of the MZL Workshop and its contributions to advancing research and improving outcomes.
